Novartis Cosentyx wins positive EU CHMP opinion for polymyalgia rheumatica after Phase III trial success
Novartis won a positive CHMP opinion backing Cosentyx for polymyalgia rheumatica, positioning it for a potential new European indication. Phase III REPLENISH results were presented at the 2026 EULAR congress, then published in the New England Journal of Medicine. The study showed Cosentyx improved sustained remission a